Navigation Links
Orthomimetics Secures CE Mark Approval for Chondromimetic
Date:1/14/2009

CAMBRIDGE, England, January 14 /PRNewswire/ -- This approval enables the company to market its line of bioresorbable implants for bone and/or soft tissue repair in the EU. Orthomimetics' family of products was developed during a groundbreaking collaboration between the University of Cambridge and the Massachusetts Institute of Technology.

Chondromimetic is a novel off-the-shelf implant that helps to support the repair of defects involving both articular cartilage and bone - defects that can result from sports injuries, surgical intervention and other trauma. Articular cartilage damage and subsequent degeneration of the underlying bone are known to be a major cause of arthritis in young individuals.

CE-mark approval enables the company to market Chondromimetic in Europe, and comes earlier than originally forecast at the time of the company's December 2006 Series A financing. Orthomimetics will immediately launch a comprehensive post-market clinical-trial program for Chondromimetic, and is currently negotiating distribution agreements for key European territories. The company will pursue additional approvals in other global territories throughout 2009.

Commenting on the CE Mark approval, Dr Andrew Lynn, CEO of Orthomimetics, said:

"Orthomimetics is extremely pleased to be able to make Chondromimetic available for surgeons and patients in Europe. This approval is the result of a tremendous amount of hard work on the part of our surgeon advisors, scientific collaborators, and - most of all - our professional, dedicated team. We look forward to making Chondromimetic a clinical and commercial success."

Editors Notes:

Orthomimetics Limited is a medical technology company that specialises in the design, development, and manufacture of regenerative medical implants and minimally invasive delivery systems for the treatment of sports injuries, trauma and other conditions that affect knees, ankles and other articular joints. Formed in 2005 as the first spin-out venture from the Cambridge-MIT Institute, the company is bringing to market a line of medical device products designed to improve the treatment outcome of first-line surgical procedures for the regenerative repair of articular cartilage, meniscus, ligament and tendon injuries using natural biomaterials. These products are engineered to be compatible with existing surgical techniques and to work in combination with emerging cell- and biologics-based products.

For further information on Orthomimetics please go to our website: http://www.orthomimetics.com or contact Katherine Webster: info@orthomimetics.com


'/>"/>
SOURCE Orthomimetics Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Precision Therapeutics Secures $43 Million in Venture Capital Funding
2. DFine Secures $30 Million in Series D Funding
3. Ocean Nutrition Canada Limited Secures Their Position as the Largest Omega-3 EPA/DHA Ingredient Supplier in the World
4. Cohera Medical Secures $16.1 Million in Series B Financing
5. Miller, Murtha & Psoras Secures Multimillion-Dollar Settlement for Victim of Industrial Accident at Bethlehem Steel
6. Almost Family Secures $75 Million Revolving Credit Facility
7. 1,000th Uninsured Virginia Patient Secures Access to Quality Medical Care Through Virginia Cares Uninsured Program (VCUP)
8. Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production
9. Global Med Technologies(R), Inc. Secures $6 Million Credit Facility From Silicon Valley Bank for Inlog Acquisition
10. PSS Systems Secures $18 Million in Financing
11. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Italy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... Paul Yost, will begin serving as new board chair for Orange County health ... will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which runs ...
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric ... Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System to his ... to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu ...
(Date:3/28/2017)... Albertson, NY (PRWEB) , ... March 28, 2017 , ... Oily skin is a common ... with Advanced Dermatology has a lot to offer to the discussion of dealing ... good news is that there are many home remedies that can help remove the oily ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... with or without a referral. Sleep apnea is often left untreated because patients are ... headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Akcea Therapeutics, a subsidiary ... to the company,s board of directors: ... Partners. Mr. Gabrieli will serve as chairman of the board ... former chief commercial officer of Forest Laboratories. ... Biolink Partners. "We are excited to ...
(Date:3/28/2017)... SAN FRANCISCO , March 28, 2017 ... is expected to reach USD 8.0 billion by 2025, ... Inc. The increasing incidence of infectious diseases and cancer ... for use in disease diagnosis over the coming years. ... the usage of autologous and allogenic stem cell therapy, ...
(Date:3/27/2017)... LONDON , March 27, 2017 ... require to better understand Eli Lilly and its partnering interests ... Alliance since 2010 report provides an in-depth insight into the ... companies. On demand company reports are prepared upon ... deal and company data. The report will be ...
Breaking Medicine Technology: